Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.

Seremet T, Jansen Y, Planken S, Njimi H, Delaunoy M, El Housni H, Awada G, Schwarze JK, Keyaerts M, Everaert H, Lienard D, Del Marmol V, Heimann P, Neyns B.

J Transl Med. 2019 Sep 5;17(1):303. doi: 10.1186/s12967-019-2051-8.

2.

MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells.

Peeters MJW, Dulkeviciute D, Draghi A, Ritter C, Rahbech A, Skadborg SK, Seremet T, Carnaz Simões AM, Martinenaite E, Halldórsdóttir HR, Andersen MH, Olofsson GH, Svane IM, Rasmussen LJ, Met Ö, Becker JC, Donia M, Desler C, Thor Straten P.

Cancer Immunol Res. 2019 Sep;7(9):1472-1484. doi: 10.1158/2326-6066.CIR-18-0841. Epub 2019 Jul 2.

PMID:
31266785
3.

Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases.

Jansen YJL, Verset G, Schats K, Van Dam PJ, Seremet T, Kockx M, Van Laethem JB, Neyns B.

ESMO Open. 2019 Mar 5;4(2):e000464. doi: 10.1136/esmoopen-2018-000464. eCollection 2019.

4.

Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma.

Sundahl N, Seremet T, Van Dorpe J, Neyns B, Ferdinande L, Meireson A, Brochez L, Kruse V, Ost P.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):828-835. doi: 10.1016/j.ijrobp.2019.03.041. Epub 2019 Apr 3.

PMID:
30951807
5.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Mäkelä S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B.

Ann Oncol. 2019 Jul 1;30(7):1154-1161. doi: 10.1093/annonc/mdz110.

PMID:
30923820
6.

Anaphylaxis-like reaction to anti-BRAF inhibitor dabrafenib confirmed by drug provocation test.

Seremet T, Haccuria A, Lienard D, Del Marmol V, Neyns B.

Melanoma Res. 2019 Feb;29(1):95-98. doi: 10.1097/CMR.0000000000000529.

PMID:
30383722
7.

Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.

Seremet T, Planken S, Schwarze JK, Jansen Y, Vandeweerd L, van den Begin R, Tsechelidis I, Lienard D, Del Marmol V, Neyns B.

Melanoma Res. 2019 Feb;29(1):85-88. doi: 10.1097/CMR.0000000000000501.

PMID:
30211812
8.

Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition.

Awada G, Seremet T, Fostier K, Everaert H, Neyns B.

Blood Adv. 2018 Aug 28;2(16):2156-2158. doi: 10.1182/bloodadvances.2018021782. No abstract available.

9.

Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.

Seremet T, Planken S, Schreuer M, Jansen Y, Delaunoy M, El Housni H, Lienard D, Del Marmol V, Heimann P, Neyns B.

Melanoma Res. 2018 Feb;28(1):65-70. doi: 10.1097/CMR.0000000000000415.

PMID:
29227333
10.

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.

Schreuer M, Jansen Y, Planken S, Chevolet I, Seremet T, Kruse V, Neyns B.

Lancet Oncol. 2017 Apr;18(4):464-472. doi: 10.1016/S1470-2045(17)30171-7. Epub 2017 Mar 4.

PMID:
28268064
11.

Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.

Seremet T, Koch A, Jansen Y, Schreuer M, Wilgenhof S, Del Marmol V, Liènard D, Thielemans K, Schats K, Kockx M, Van Criekinge W, Coulie PG, De Meyer T, van Baren N, Neyns B.

J Transl Med. 2016 Aug 2;14(1):232. doi: 10.1186/s12967-016-0990-x.

12.

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.

Schreuer M, Meersseman G, Van Den Herrewegen S, Jansen Y, Chevolet I, Bott A, Wilgenhof S, Seremet T, Jacobs B, Buyl R, Maertens G, Neyns B.

J Transl Med. 2016 Apr 19;14:95. doi: 10.1186/s12967-016-0852-6.

13.

Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma.

Schreuer M, Meersseman G, van Den Herrewegen S, Jansen Y, Seremet T, Bott A, Chevolet I, Wilgenhof S, Maertens G, Neyns B.

Melanoma Res. 2016 Apr;26(2):157-63. doi: 10.1097/CMR.0000000000000224.

PMID:
26636909
14.

Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.

Jansen YJ, Janssens P, Hoorens A, Schreuer MS, Seremet T, Wilgenhof S, Neyns B.

Melanoma Res. 2015 Dec;25(6):550-4. doi: 10.1097/CMR.0000000000000186.

PMID:
26512791
16.

Design and validation of conditional ligands for HLA-B*08:01, HLA-B*15:01, HLA-B*35:01, and HLA-B*44:05.

Frøsig TM, Yap J, Seremet T, Lyngaa R, Svane IM, Thor Straten P, Heemskerk MH, Grotenbreg GM, Hadrup SR.

Cytometry A. 2015 Oct;87(10):967-75. doi: 10.1002/cyto.a.22689. Epub 2015 Jun 1.

17.

Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.

Seremet T, Lienard D, Suppa M, Trepant AL, Rorive S, Woff E, Cuylits N, Jansen Y, Schreuer M, Del Marmol V, Neyns B.

Melanoma Res. 2015 Apr;25(2):180-3. doi: 10.1097/CMR.0000000000000145.

PMID:
25643238
18.

Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure.

Schreuer MS, Chevolet IL, Jansen YJ, Seremet TC, Wilgenhof S, Liénard D, Del Marmol V, Neyns B.

Melanoma Res. 2015 Feb;25(1):68-74. doi: 10.1097/CMR.0000000000000131.

PMID:
25396684
19.

Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases.

Cipponi A, Mercier M, Seremet T, Baurain JF, Théate I, van den Oord J, Stas M, Boon T, Coulie PG, van Baren N.

Cancer Res. 2012 Aug 15;72(16):3997-4007. Epub 2012 Jul 31.

20.

Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.

Seremet T, Brasseur F, Coulie PG.

Cancer J. 2011 Sep-Oct;17(5):325-30. doi: 10.1097/PPO.0b013e3182326004. Review.

PMID:
21952282
21.

Longitudinal immune monitoring of patients receiving intratumoral injection of a MART-1 T-cell receptor-transduced cell line (C-Cure 709).

Køllgaard T, Duval L, Schmidt H, Kaltoft K, Seremet T, Andersen MH, Maase Hv, Straten Pt, Hadrup SR.

Cytotherapy. 2009;11(5):631-41. doi: 10.1080/14653240902923146.

PMID:
19530030
22.

The 1170 A-P single-nucleotide polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility antigen (mHag).

Wenandy L, Kollgaard T, Letsch A, Andersen RS, Stather D, Seremet T, Svane IM, Vindeløv L, Andersen MH, thor Straten P.

Leukemia. 2009 Oct;23(10):1926-9. doi: 10.1038/leu.2009.112. Epub 2009 May 21. No abstract available.

PMID:
19458631
23.

Reactivity of naive CD4+CD25- T cells against gut microflora in healthy mice.

Gad M, Lundsgaard D, Kjellev S, Kristensen NN, Seremet T, Straten PT, Claesson MH.

Int Immunol. 2006 May;18(5):817-25. Epub 2006 Mar 30.

PMID:
16574668
24.

Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells.

Hadrup SR, Braendstrup O, Jacobsen GK, Mortensen S, Pedersen LØ, Seremet T, Andersen MH, Becker JC, Straten PT.

Int J Cancer. 2006 Aug 15;119(4):831-8.

25.

Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly.

Hadrup SR, Strindhall J, Køllgaard T, Seremet T, Johansson B, Pawelec G, thor Straten P, Wikby A.

J Immunol. 2006 Feb 15;176(4):2645-53.

26.

Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation.

Kollgaard T, Petersen SL, Hadrup SR, Masmas TN, Seremet T, Andersen MH, Madsen HO, Vindeløv L, thor Straten P.

Leukemia. 2005 Dec;19(12):2273-80.

PMID:
16304575
27.

Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes.

Straten Pt, Dahl C, Schrama D, Pedersen LØ, Andersen MH, Seremet T, Bröcker EB, Guldberg P, Becker JC.

Cancer Immunol Immunother. 2006 May;55(5):495-502. Epub 2005 Jul 7.

PMID:
16001163
28.

In situ cytokine therapy: redistribution of clonally expanded T cells.

thor Straten P, Guldberg P, Schrama D, Andersen MH, Moerch U, Seremet T, Siedel C, Reisfeld RA, Becker JC.

Eur J Immunol. 2001 Jan;31(1):250-8.

29.

Comparative delineation of T cell clonotypes in coexisting syngeneic B16 melanoma.

Moerch U, Schrama D, Guldberg P, Seremet T, Zeuthen J, Becker JC, thor Straten P.

Cancer Immunol Immunother. 2000 Oct;49(8):426-32.

PMID:
11043849
30.

Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture.

thor Straten P, Kirkin AF, Siim E, Dahlström K, Drzewiecki KT, Seremet T, Zeuthen J, Becker JC, Guldberg P.

Clin Immunol. 2000 Aug;96(2):94-9.

PMID:
10900156
31.

In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes.

thor Straten P, Guldberg P, Grønbaek K, Hansen MR, Kirkin AF, Seremet T, Zeuthen J, Becker JC.

J Immunol. 1999 Jul 1;163(1):443-7.

32.

Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma.

Guldberg P, thor Straten P, Ahrenkiel V, Seremet T, Kirkin AF, Zeuthen J.

Oncogene. 1999 Mar 4;18(9):1777-80.

33.

Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DGGE).

thor Straten P, Barfoed A, Seremet T, Saeterdal I, Zeuthen J, Guldberg P.

Biotechniques. 1998 Aug;25(2):244-50.

34.

Activation of preexisting T cell clones by targeted interleukin 2 therapy.

Straten PT, Guldberg P, Seremet T, Reisfeld RA, Zeuthen J, Becker JC.

Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8785-90.

35.

T-cell receptor variable region genes in cutaneous T-cell lymphomas.

Thor Straten P, Ralfkiaer E, Hendriks J, Seremet T, Vejlsgaard GL, Zeuthen J.

Br J Dermatol. 1998 Jan;138(1):3-12.

PMID:
9536217
36.

Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines.

Thor Straten P, Kirkin AF, Seremet T, Zeuthen J.

Int J Cancer. 1997 Mar 4;70(5):582-6.

37.

Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma.

thor Straten P, Becker JC, Seremet T, Bröcker EB, Zeuthen J.

J Clin Invest. 1996 Jul 15;98(2):279-84.

38.
39.

Evidence for human antibodies that recognize an aflatoxin epitope in groups with high and low exposure to aflatoxins.

Autrup H, Seremet T, Wakhisi J.

Arch Environ Health. 1990 Jan-Feb;45(1):31-4.

PMID:
1690532
41.

Excretion of benzo[a]pyrene-Gua adduct in the urine of benzo[a]pyrene-treated rats.

Autrup H, Seremet T.

Chem Biol Interact. 1986 Nov;60(2):217-26.

PMID:
3791489
42.

Metabolism of benzo[a]pyrene by cultured rat and human buccal mucosa cells.

Autrup H, Seremet T, Arenholt D, Dragsted L, Jepsen A.

Carcinogenesis. 1985 Dec;6(12):1761-5.

PMID:
4064251

Supplemental Content

Loading ...
Support Center